On December 6, 2021 AIM ImmunoTech Inc. (NYSE American: AIM) reported that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences (Press release, AIM ImmunoTech, DEC 6, 2021, View Source [SID1234596532]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioFlorida Conference
Mr. Equels will be participating in the "COVID-19: What’s Next in Prevention, Treatment & Diagnostics" panel taking place on Thursday, December 9, 2021 at 1:45 PM EST during the BioFlorida Conference. He will also be participating in the CEO Forum at 5:30 PM EST.

The BioFlorida conference will consist of a series of roundtable panel discussions that will be moderated by Maulik Shah, MD, PhD, from Applied Ingenuity Diagnostics.

For more information on the BioFlorida Conference, please visit BioFlorida.com or contact [email protected].

Benzinga All-Access Event
Mr. Equels is scheduled to participate on December 16, 2021 at 11:20 AM EST during the Benzinga All Access event. The event will be broadcast live and can be viewed here. An archived recording of the presentation will be available on the investor relations section of the AIM website at View Source

The Benzinga All Access Show is a 2-hour talk-show event where a select number of companies are chosen to give a 20-minute interview to discuss their companies. Benzinga All Access is a first-of-its-kind show: part interview, part investor presentation. On All Access, Benzinga partners with companies to bring you in-depth one-on-one conversations with executives across a wide range of industries and asset classes.